CrossPoint Therapeutics
CrossPoint Therapeutics is a biotech company founded in October 2022, specializing in innovative antibody drug development using its proprietary Stealth-Body antibody platform technology. The company aims to overcome limitations in antibody-based drug development, particularly by reducing toxicity and side effects associated with antibody therapies, and expanding treatment options for intractable diseases. It actively collaborates with academic and industry partners to develop next-generation therapeutics, including ADCs and immune-modulating agents, with a focus on safety, efficacy, and broadening the scope of treatable diseases.
Industries
Nr. of Employees
small (1-50)
CrossPoint Therapeutics
1306 593-8 Dongtangiheung-ro Hwaseong-si Gyeonggi-do Republic of Korea
Products
CPP-001 (protein delivery project)
Pipeline program using antibody-targeted delivery to transport therapeutic proteins selectively to disease cells.
CPS-001 (small-molecule delivery project)
Pipeline program aimed at antibody-mediated delivery of small-molecule payloads to improve target selectivity and therapeutic index.
CPR-001 (gene delivery project)
Pipeline program focused on antibody‑mediated gene delivery for targeted modulation of RNA or gene expression in specific cell populations.
CPP-001 (protein delivery project)
Pipeline program using antibody-targeted delivery to transport therapeutic proteins selectively to disease cells.
CPS-001 (small-molecule delivery project)
Pipeline program aimed at antibody-mediated delivery of small-molecule payloads to improve target selectivity and therapeutic index.
CPR-001 (gene delivery project)
Pipeline program focused on antibody‑mediated gene delivery for targeted modulation of RNA or gene expression in specific cell populations.
Services
Licensing of antibody Fc‑silencing platform and collaborative R&D with academic and industry partners to develop modality-specific programs.
Joint development agreements with contract development and analysis organizations to provide process development, analytical method support, and manufacturing pathways for ADC programs.
Licensing of antibody Fc‑silencing platform and collaborative R&D with academic and industry partners to develop modality-specific programs.
Joint development agreements with contract development and analysis organizations to provide process development, analytical method support, and manufacturing pathways for ADC programs.
Expertise Areas
- Antibody engineering and Fc modulation
- Antibody-drug conjugate (ADC) development
- Targeted delivery of proteins, small molecules, and genes
- Preclinical study design and in vivo validation
Key Technologies
- Fc silencing / Fc engineering
- Antibody-drug conjugation (ADC)
- Bispecific antibody design
- Antibody-mediated protein delivery
News & Updates
CrossPoint was selected for the Ministry of SMEs and Startups' Deep Tech TIPS program in 2024, supporting the development of next-generation drugs including ADCs and immune-modulating therapies.
CrossPoint was selected for the Deep Tech TIPS program in 2024, supporting its innovative platform technology for antibody drug development.
CrossPoint was selected for the Ministry of SMEs and Startups' Deep Tech TIPS program in 2024, supporting the development of next-generation drugs including ADCs and immune-modulating therapies.
CrossPoint was selected for the Deep Tech TIPS program in 2024, supporting its innovative platform technology for antibody drug development.